OpGen

OpGen EBIT Margin

The EBIT Margin (Operating Margin) of OpGen (OPGN) as of Oct 19, 2026 is 79.56 %. In the previous year, EBIT Margin (Operating Margin) was 7.70 % — a change of 933.93% (higher).

EBIT Margin

79.56 %

YoY

933.93%

Last updated:

EBIT Margin (Operating Margin) of OpGen is 2025 79.56 % . EBIT Margin (Operating Margin) of OpGen was 2024 7.70 % . It decreases by 933.93% higher compared to the previous year.

OpGen's operating (EBIT) margin stands at 79.6%, up from -540.5% several years earlier.

The OpGen EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-447.39 USD
Jan 1, 2019
-350.70 USD
Jan 1, 2020
-510.09 USD
Jan 1, 2021
-540.48 USD
Jan 1, 2022
-852.28 USD
Jan 1, 2023
-458.98 USD
Jan 1, 2024
7.70 USD
Jan 1, 2025
79.56 USD
The OpGen EBIT Margin history
YEAREBIT MarginYoY
79.56 %+933.93%
7.70 %-101.68%
-458.98 %-46.15%
-852.28 %+57.69%
-540.48 %+5.96%
-510.09 %+45.45%
-350.70 %-21.61%
-447.39 %-5.73%
-474.60 %+0.51%
-472.20 %+2.61%
-460.20 %+241.20%
-134.88 %+3,047.99%
-4.28 %+178.09%
-1.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

EBIT Margin (Operating Margin) of OpGen is 79.56 % in 2025.

EBIT Margin (Operating Margin) of OpGen changed from 7.70 % to 79.56 %, representing a 933.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) OpGen since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — OpGen

All Key Metrics — OpGen